Core Insights - National strategic investment platform Guotou Juli has completed a strategic investment of 450 million yuan in leading synthetic biology company Yikole Biotechnology [1] - Yikole's core competitiveness lies in its platform-based technology system, effectively overcoming the core bottleneck of "engineering transformation" in biological manufacturing [1] - The company has successfully achieved seamless scaling from "gram-level research" to "thousand-ton-level production" through its complete technology path and eight innovative technology platforms [1] Industry Positioning - Yikole is set to be the first in China to achieve market approval for high-value functional raw materials such as human milk oligosaccharides (HMOs), steviol glycosides, and nest acid from 2023 to 2025, gaining a first-mover advantage [2] - The company has established over 20 mature product lines in the fields of biomedicine, green agriculture, and life health [2] - Yikole has formed joint ventures with industry leaders, such as "Hongmo Bio" with Mengniu Group for HMOs commercialization and "Yikotang" with Jinhwa Industrial for health sweetener operations [2] Strategic Collaboration - Guotou Juli's investment aligns with the national strategy to accelerate the development of biological manufacturing and create new productive forces [3] - The collaboration will focus on innovative platform construction and cutting-edge technology application research [3] - Both parties will prioritize advancing biosynthesis technology using carbon compounds like carbon dioxide, carbon monoxide, and methanol, supporting the sustainable development strategy of "not competing with food for land or grain" [3]